Cargando…
Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020)
Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769541/ https://www.ncbi.nlm.nih.gov/pubmed/35085926 http://dx.doi.org/10.1016/j.ejmech.2022.114136 |
_version_ | 1784635167622561792 |
---|---|
author | Denel-Bobrowska, Marta Olejniczak, Agnieszka B. |
author_facet | Denel-Bobrowska, Marta Olejniczak, Agnieszka B. |
author_sort | Denel-Bobrowska, Marta |
collection | PubMed |
description | Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of selected synthetic antiviral agents not associated to nucleosides developed against human viruses and introduced to preclinical and clinical trials as well as drugs approved for antiviral therapy over the last 10 years. The article describes for the first time the wide classification of such antiviral drugs and drug candidates and briefly summarizes the biological target and clinical applications of the compounds. The described compounds are arranged according to the antiviral mechanism of action. Knowledge of the drug's activity toward specific molecular targets may be the key to researching new antiviral compounds and repositioning drugs already approved for clinical use. The paper also briefly discusses the future directions of antiviral therapy. The described examples of antiviral compounds can be helpful for further drug development. |
format | Online Article Text |
id | pubmed-8769541 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87695412022-01-20 Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) Denel-Bobrowska, Marta Olejniczak, Agnieszka B. Eur J Med Chem Article Nucleosides and their derivatives are a well-known and well-described class of compounds with antiviral activity. Currently, in the era of the COVID-19 pandemic, scientists are also looking for compounds not related to nucleosides with antiviral properties. This review aims to provide an overview of selected synthetic antiviral agents not associated to nucleosides developed against human viruses and introduced to preclinical and clinical trials as well as drugs approved for antiviral therapy over the last 10 years. The article describes for the first time the wide classification of such antiviral drugs and drug candidates and briefly summarizes the biological target and clinical applications of the compounds. The described compounds are arranged according to the antiviral mechanism of action. Knowledge of the drug's activity toward specific molecular targets may be the key to researching new antiviral compounds and repositioning drugs already approved for clinical use. The paper also briefly discusses the future directions of antiviral therapy. The described examples of antiviral compounds can be helpful for further drug development. Elsevier Masson SAS. 2022-03-05 2022-01-19 /pmc/articles/PMC8769541/ /pubmed/35085926 http://dx.doi.org/10.1016/j.ejmech.2022.114136 Text en © 2022 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Denel-Bobrowska, Marta Olejniczak, Agnieszka B. Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
title | Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
title_full | Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
title_fullStr | Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
title_full_unstemmed | Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
title_short | Non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
title_sort | non-nucleoside structured compounds with antiviral activity—past 10 years (2010–2020) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769541/ https://www.ncbi.nlm.nih.gov/pubmed/35085926 http://dx.doi.org/10.1016/j.ejmech.2022.114136 |
work_keys_str_mv | AT denelbobrowskamarta nonnucleosidestructuredcompoundswithantiviralactivitypast10years20102020 AT olejniczakagnieszkab nonnucleosidestructuredcompoundswithantiviralactivitypast10years20102020 |